Skip to main content
Top
Published in: Journal of General Internal Medicine 7/2020

01-07-2020 | Insomnia | Original Research

Medical Reasons for Marijuana Use, Forms of Use, and Patient Perception of Physician Attitudes Among the US Population

Authors: Patrick M. Azcarate, MD, Alysandra J. Zhang, BA, Salomeh Keyhani, MD MPH, Stacey Steigerwald, MSSA, Julie H. Ishida, MD, MAS, MPH, Beth E. Cohen, MD MAS

Published in: Journal of General Internal Medicine | Issue 7/2020

Login to get access

Abstract

Background

The use of marijuana for medical purposes is increasing in parallel with expanding legalization and decreased public perception of harm. Despite this increase in use, it is unclear which medical conditions patients are attempting to treat with marijuana and whether they are communicating with medical providers about their use.

Objective

To understand the medical reasons for marijuana use, forms of marijuana used for medical purposes, and disclosure of use to physicians.

Design

National, probability-based online survey.

Setting

The USA, 2017.

Participants

16,280 US adults.

Main Measure

Proportion of US adults who agreed with a statement.

Key Results

A total of 9003 participants completed the survey (55% response rate). Five hundred ninety-one (7% of US adults) reported using marijuana for medical purposes. The most common medical reasons for marijuana use were anxiety (49%), insomnia (47%), chronic pain (42%), and depression (39%). The most common forms of use for all medical conditions were smoking and edibles, followed by vaping, concentrate, and topical. We found women were more likely to use marijuana for posttraumatic stress disorder, sleep, anxiety, and migraines. We did not find substantial variation in medical reasons for marijuana use by race. Among those using marijuana for medical purposes, 21% did not have a doctor. Among those with doctors, 33% did not inform them, 28% reported their doctor was neutral on their use, 32% reported their doctor was supportive, and 8% reported their doctor was not supportive. Those who lived in states where medical marijuana was illegal were less likely to disclose use to their doctor.

Limitation

The online format of the survey may have caused selection bias. Wording of the questions may have affected interpretation. Doctors were not queried directly, rather participants were asked about their perception of doctor attitudes.

Conclusion

Americans are using marijuana to treat medical conditions despite lack of evidence of efficacy.
Appendix
Available only for authorised users
Literature
6.
go back to reference The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC, US: National Academies Press; 2017. xviii, 468-xviii, p. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC, US: National Academies Press; 2017. xviii, 468-xviii, p.
7.
go back to reference Brust J, Fee D, Pushpa Narayanaswami P, Patel A, Song S, Youssof S, et al. Position statement: Use of Medical Marijuana for Neurologic Disorders. Am Acad Neurol. 2018. Brust J, Fee D, Pushpa Narayanaswami P, Patel A, Song S, Youssof S, et al. Position statement: Use of Medical Marijuana for Neurologic Disorders. Am Acad Neurol. 2018.
12.
13.
go back to reference Nunberg H, Kilmer B, Pacula RL, Burgdorf J. An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California. J Drug Policy Analy. 2011;4(1). Nunberg H, Kilmer B, Pacula RL, Burgdorf J. An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California. J Drug Policy Analy. 2011;4(1).
15.
18.
go back to reference Lin LA, Ilgen MA, Jannausch M, Bohnert KM. Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample. Addict Behav. 2016;61:99–103.CrossRefPubMedPubMedCentral Lin LA, Ilgen MA, Jannausch M, Bohnert KM. Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample. Addict Behav. 2016;61:99–103.CrossRefPubMedPubMedCentral
19.
go back to reference Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. Addiction. 2016;111(6):973–80.CrossRefPubMedPubMedCentral Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. Addiction. 2016;111(6):973–80.CrossRefPubMedPubMedCentral
20.
go back to reference Hasin DS. US Epidemiology of Cannabis Use and Associated Problems. Neuropsychopharmacology. 2018;43(1):195–212CrossRefPubMed Hasin DS. US Epidemiology of Cannabis Use and Associated Problems. Neuropsychopharmacology. 2018;43(1):195–212CrossRefPubMed
21.
go back to reference Cerda M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012;120(1–3):22–7.CrossRefPubMed Cerda M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012;120(1–3):22–7.CrossRefPubMed
22.
go back to reference Hasin DS, Grant B. NESARC Findings on Increased Prevalence of Marijuana Use Disorders-Consistent With Other Sources of Information. JAMA Psychiatry. 2016;73(5):532.CrossRefPubMedPubMedCentral Hasin DS, Grant B. NESARC Findings on Increased Prevalence of Marijuana Use Disorders-Consistent With Other Sources of Information. JAMA Psychiatry. 2016;73(5):532.CrossRefPubMedPubMedCentral
23.
go back to reference Azofeifa A, Mattson ME, Schauer G, McAfee T, Grant A, Lyerla R. National Estimates of Marijuana Use and Related Indicators - National Survey on Drug Use and Health, United States, 2002–2014. Morb Mortal Wkly Rep Surveill Summ (Washington, DC: 2002). 2016;65(11):1–28 Azofeifa A, Mattson ME, Schauer G, McAfee T, Grant A, Lyerla R. National Estimates of Marijuana Use and Related Indicators - National Survey on Drug Use and Health, United States, 2002–2014. Morb Mortal Wkly Rep Surveill Summ (Washington, DC: 2002). 2016;65(11):1–28
25.
go back to reference Research AAfPO. Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. Oakbrook Terrace, IL: AAPOR, 2016. Research AAfPO. Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. Oakbrook Terrace, IL: AAPOR, 2016.
27.
go back to reference Sexton M, Cuttler C, Finnell JS, Mischley LK. A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy. (2378–8763 (Print)). Sexton M, Cuttler C, Finnell JS, Mischley LK. A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy. (2378–8763 (Print)).
32.
go back to reference Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med. 2007;167(3):221–8.CrossRefPubMedPubMedCentral Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med. 2007;167(3):221–8.CrossRefPubMedPubMedCentral
33.
go back to reference Ghasemiesfe M, Ravi D, Vali M, Korenstein D, Arjomandi M, Frank J, et al. Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Ann Intern Med. 2018;169(2):106–15.CrossRefPubMedPubMedCentral Ghasemiesfe M, Ravi D, Vali M, Korenstein D, Arjomandi M, Frank J, et al. Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Ann Intern Med. 2018;169(2):106–15.CrossRefPubMedPubMedCentral
35.
go back to reference Frost L, Mostofsky E, Rosenbloom JI, Mukamal KJ, Mittleman MA. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J. 2013;165(2):170–5.CrossRefPubMed Frost L, Mostofsky E, Rosenbloom JI, Mukamal KJ, Mittleman MA. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J. 2013;165(2):170–5.CrossRefPubMed
36.
go back to reference Cuttler C, Mischley LK, Sexton M. Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users. Cannabis Cannabinoid Res. 2016;1(1):166–75.CrossRefPubMedPubMedCentral Cuttler C, Mischley LK, Sexton M. Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users. Cannabis Cannabinoid Res. 2016;1(1):166–75.CrossRefPubMedPubMedCentral
37.
go back to reference Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2009;35(5):937–48.CrossRefPubMed Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2009;35(5):937–48.CrossRefPubMed
40.
go back to reference Braun IM, Wright A, Peteet J, Meyer FL, Yuppa DP, Bolcic-Jankovic D, et al. Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study. (1527–7755 (Electronic)). Braun IM, Wright A, Peteet J, Meyer FL, Yuppa DP, Bolcic-Jankovic D, et al. Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study. (1527–7755 (Electronic)).
41.
go back to reference Clancy CM. Access to VHA clinical programs for veterans participating in state-approved marijuana programs. In: Veterans Health Administration DoVA, editor. Washington, DC 2017. Clancy CM. Access to VHA clinical programs for veterans participating in state-approved marijuana programs. In: Veterans Health Administration DoVA, editor. Washington, DC 2017.
Metadata
Title
Medical Reasons for Marijuana Use, Forms of Use, and Patient Perception of Physician Attitudes Among the US Population
Authors
Patrick M. Azcarate, MD
Alysandra J. Zhang, BA
Salomeh Keyhani, MD MPH
Stacey Steigerwald, MSSA
Julie H. Ishida, MD, MAS, MPH
Beth E. Cohen, MD MAS
Publication date
01-07-2020
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 7/2020
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-05800-7

Other articles of this Issue 7/2020

Journal of General Internal Medicine 7/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.